Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17601685 | 1.00 | S1PR1 (0.53) | S1PR1MAOBPPARAPPARGSLC6A5 | |
| SCHEMBL17601727 | 0.90 | S1PR1 (0.53) | S1PR1MAOBPPARAPPARGSLC6A5 | |
| SCHEMBL17601726 | 0.90 | S1PR1 (0.53) | S1PR1MAOBPPARAPPARGSLC6A5 | |
| SCHEMBL16914932 | 0.83 | S1PR1 (0.55) | S1PR1MAOBPPARAPPARGMME | |
| SCHEMBL17601782 | 0.83 | S1PR1 (0.55) | S1PR1MAOBPPARAPPARGMME | |
| SCHEMBL17601744 | 0.82 | MAOB (0.53) | S1PR1MAOBPPARAPPARGSLC6A5 | |
| SCHEMBL16915155 | 0.82 | MAOB (0.53) | S1PR1MAOBPPARAPPARGSLC6A5 | |
| SCHEMBL16269797 | 0.82 | MAOB (0.55) | S1PR1MAOBPPARAPPARGSLC6A5 | |
| SCHEMBL16269794 | 0.82 | MAOB (0.55) | S1PR1MAOBPPARAPPARGSLC6A5 | |
| SCHEMBL16379337 | 0.82 | ALDH1A1 (0.50) | MAOBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083380-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083380-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | OAT, CYP11B2, CYP11B1 | S1PR1 1228/4885MAOB 220/4885PPARA 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.